$Immuneering (IMRX.US)$I feel truly grateful to have had the opportunity to invest in Immuneering (IMRX) at such an early stage. I firmly believe in the potential of this company and the groundbreaking work they’re doing. The drugs they’re developing have the capacity to make a significant difference in the lives of so many people, and that’s something I deeply resonate with. The results they’ve achieved so far are nothing short of incredible, and it fills me with immense hope and gratitude. I tr...

$Immuneering (IMRX.US)$ IMRX is bursting with potential, a stock teeming with endless possibilities across multiple realities! No matter which path you envision, they all lead to the same thrilling destination—upward momentum. The only question is, how high will it go? Buckle up!

$Immuneering (IMRX.US)$ $IMRX Immuneering isn’t just another biotech. They’re rewriting the rules of drug discovery using advanced bioinformatics, aiming to outsmart diseases at the molecular level. Their Deep Informatics Platform analyzes vast biological datasets to find hidden drug targets—essentially bringing AI-power
🧬 A New Kind of Drug Design: Unlike traditional drugs that hit their targets constantly, Immuneering’s “Deep Cyclic Inhibition” strategy uses pulsed dosing to give cancer cells j...

$Immuneering (IMRX.US)$Yes, Immuneering Corporation is scheduled to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. The presentation will take place from 2:40 PM to 3:10 PM Eastern Time (11:40 AM to 12:10 PM Pacific Time) in Track 2. During this virtual event, CEO Ben Zeskind and Chief Scientific Officer Brett Hall will discuss the company’s pipeline, platform, and business strategy. The presentation will be webcast live and archived in the Investo...

$Immuneering (IMRX.US)$ Immuneering Corporation (NASDAQ: IMRX) has received varied price targets from analysts, reflecting optimism about its potential. Currently trading at $1.86 per share, targets range from $8.00 to $25.00, with an average of around $12.00, suggesting significant upside. Notably, Needham reaffirmed a $12.00 target, and Mizuho initiated coverage with a $10.00 target. These figures indicate potential growth, but the broad range highlights uncertainties typical of developmental b...

$Immuneering (IMRX.US)$ Immuneering Corporation has announced a clinical supply agreement with Regeneron Pharmaceuticals to evaluate the combination of Immuneering’s lead product candidate, IMM-1-104, with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab). This collaboration aims to assess the efficacy of this combination in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC) as part of Immuneering’s ongoing Phase 2a clinical trial.
Under the terms of the agr...

$Immuneering (IMRX.US)$
I will buy 100 more shares when it hits $2.25

$Immuneering (IMRX.US)$ running of the Bulls

$Immuneering (IMRX.US)$ i  glad i only bought 3 shares

$Immuneering (IMRX.US)$
I am trying through some sort of astroprojection to create an alliance a collection of projected realities that induce the stock to $15 to the point where it will be one day we all know it we all know it will be well past that point
In reality we are experiencing together
I see $15 coming very quickly. I'm lining with it. I'm seeing it. I'm not worrying about it. It's gonna happen. It's gonna happen very fast.
I'm lining with everything and pushing towards cancer research ...